CVRx
Neuromodulation device for heart failure treatment
Area Vice President - Sales, Medtech / Medical Device, Remote, Eastern United States
+ Variable incentive plan + Stock purchase plan + Stock options + RSU grants
Fully remote within the United States, with 60–75% travel by car and/or air within the continental US.
About the job
- A bachelor's degree is required.
- At least 15 years of progressive commercial leadership experience within the medical device industry is required.
- Demonstrated success leading second-line commercial leaders across geographically dispersed organizations is required.
- Proven experience commercializing innovative therapies requiring physician adoption, multidisciplinary collaboration, reimbursement challenge navigation, and long sales cycles is required.
- Demonstrated success recruiting, developing, coaching, and retaining high-performing commercial leaders is required.
- Experience driving organizational change and building leadership capability is required.
- Experience building scalable commercial operating models and improving commercial execution is required.
- Strong understanding of healthcare economics, reimbursement, Integrated Delivery Networks, and hospital purchasing environments is required.
- Experience using customer relationship management platforms, commercial analytics, forecasting tools, and business planning processes is required.
- Reliable home office technology and adherence to privacy commitments are required.
- Ability to travel by car and/or air 60–75% of the time is required.
- Ability to work effectively in a fast-paced, high-growth commercial environment and pivot as needed is required.
- Compliance with company policies, regulatory requirements, and customer credentialing requirements is required.
- Partner with the Chief Revenue Officer to develop and execute regional commercial strategies that drive revenue growth, market expansion, and long-term adoption of Barostim Therapy.
- Lead annual business plan execution while achieving or exceeding revenue, profitability, and market share objectives.
- Drive adoption of Barostim Therapy by expanding and strengthening strategic Barostim Programs within targeted health systems and accounts.
- Identify emerging market opportunities, competitive threats, and evolving customer needs to refine regional strategy.
- Develop and maintain knowledge of heart failure treatment pathways, competitive therapies, reimbursement dynamics, and evolving healthcare delivery models.
- Build and maintain executive-level relationships with physicians, hospital administrators, and health system leaders.
- Develop Area Sales Directors through coaching, mentoring, succession planning, and ongoing leadership development.
- Establish performance expectations and a culture of accountability, ownership, and continuous improvement.
- Build leadership capability supporting disciplined execution, commercial tool utilization, standardized processes, forecasting accuracy, and accountability across regions.
- Conduct talent calibration and performance reviews to identify future leaders and address development opportunities.
- Own the quality of commercial talent across the assigned region in partnership with Talent Acquisition and Human Resources.
- Drive standardized hiring practices using Success Profiles and behavioral interviewing methodologies.
- Lead selection decisions for Area Sales Directors and partner on executive-level commercial leadership hiring.
- Coach hiring managers to improve interviewing effectiveness, selection quality, and decision consistency.
- Build diverse, high-performing teams and strengthen leadership bench and succession readiness.
- Ensure new commercial team members achieve proficiency through standardized onboarding, coaching, and performance development.
- Partner with Commercial Training on standardized onboarding and cohort-based development initiatives.
- Monitor early performance indicators, coaching effectiveness, and time-to-productivity for newly hired employees.
- Drive retention of top talent through proactive development planning and leadership engagement.
- Drive commercial strategy execution through pipeline management, commercial tool utilization, standardized processes, customer relationship management discipline, forecasting, business planning, and performance analytics.
- Establish business and pipeline reviews, forecasting, coaching, and accountability cadences across the region.
- Monitor key performance indicators to identify opportunities, remove barriers, and improve execution.
- Ensure compliance with corporate policies, regulatory requirements, and quality standards.
- Manage regional budgets and optimize investments to achieve commercial objectives.
- Balance enterprise standards with regional market needs while executing the commercial operating model.
- Partner with Marketing, Clinical Affairs, Market Access, Medical Affairs, Commercial Operations, Finance, Human Resources, and Talent Acquisition.
- Communicate customer insights, competitive intelligence, and emerging market trends to executive leadership.
- Lead organizational change initiatives that improve commercial effectiveness and business performance.
- Experience selling disruptive devices is preferred.
- An advanced degree, such as an MBA or master's degree, is preferred.
- Prior experience with devices intended to treat heart failure is ideal.
- Experience in a high-growth or startup company is highly desirable.
- Salesforce.com experience is preferred.
About the company
CVRx develops BAROSTIM NEO, a neuromodulation therapy for heart failure. The device delivers electrical stimuli to baroreceptors in the cardiovascular system to modulate nerve activity and support blood pressure regulation, aiming to improve heart function in patients who struggle with fatigue, shortness of breath, and fluid retention. The system works through an implanted or wearable neuromodulation device that interacts with the body's nerve signals to influence cardiovascular control. CVRx differentiates itself by offering a focused solution for heart failure that combines the device with provider-focused support programs to facilitate patient access and reimbursement, working with hospitals and clinics to implement therapy. The company's goal is to improve patient outcomes for heart failure and expand the adoption of BAROSTIM THERAPY by helping healthcare providers treat more patients effectively.
Company Size
201-500
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
2001
Get referred to CVRx
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 16% to $15.7 million, with 87% gross margin.
- Traditional Medicare claims paid at 96% in Q2 2026.
- CMS's 2027 OPPS proposal supported Barostim placement at roughly $45,000 per procedure.
What critics are saying
- May 14, 2026 DOJ CID targets Barostim marketing, kickbacks, and false-claims allegations.
- August 6, 2026 guidance cut to $58-$60 million exposed sales-force turnover and retraining.
- August 2026 payer denials and CRO exit threaten Barostim's U.S. commercial expansion entirely.
What makes CVRx unique
- Barostim remains the only FDA-approved neuromodulation device for heart failure symptoms, as of 2026.
- January 1, 2026 Category I CPT codes strengthened reimbursement and billing permanence.
- CVRx's carotid baroreceptor mechanism differentiates it from congestion drugs and CRT hardware.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Stock Options
Company Equity
Paid Holidays
Parental Leave
Flexible Work Hours
Remote Work Options
Training Programs
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -1%2 year growth
↓ -1%CVRx reported second-quarter 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the medical device company lowered its full-year revenue guidance due to anticipated weakness in the second half of the year. CEO Kevin Hykes attributed the revised outlook to challenges with sales force integration. The company maintained 56 US sales territories, but approximately 60% of quota-carrying territory managers joined within the past 18 months. This rapid hiring pace has strained onboarding and training processes. The company cited high turnover rates, slower productivity ramp-up for new hires, and concentration of new employees in specific regions as primary factors affecting performance. Despite these challenges, regions with stable leadership and experienced teams are achieving strong double-digit growth, suggesting the company's strategy remains sound where properly executed.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, encourages CVRx Inc. (CVRX) Investors with substantial losses to Contact firm: investigating potential securities fraud following 59% stock drop. SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) - Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. CVRx Inc. (NASDAQ: CVRX) Investors: Investors who suffered substantial losses are encouraged to submit your losses now to evaluate their legal rights and recovery options. * Visit: www.hbsslaw.com/cases/cvrx * Contact Partner Reed Kathrein: 844-916-0895 | [email protected] INVESTIGATION OVERVIEW: CVRx Inc. (NASDAQ: CVRX) "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer,..." CVRx's sole commercial product is Barostim, an FDA-approved implantable neuromodulation device designed to improve symptoms for patients suffering from heart failure. Historically, CVRx assured investors that its growth strategy was anchored by a complete sales force transformation and high approval rates from Medicare Advantage payers. CVRx repeatedly highlighted a "$10.5 billion market opportunity" with less than 1% penetration, reassuring the market earlier this year that its sales force transformation was "largely complete." However, after market close on August 6, 2026, CVRx disclosed a series of severe operational and legal headwinds: * DOJ Civil Investigative Demand (CID): On May 14, 2026, CVRx received a CID from the U.S. Department of Justice investigating whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information. * Sales Force Deterioration & Guidance Cut: CVRx significantly cut its 2026 revenue expectations and revealed serious problems with its salesforce - sequentially flat growth in sales territories, turnover, and strained onboarding and training. * Medicare Advantage Approval Collapse: CVRx revealed that its primary Medicare Advantage payer - which historically approved 80% of prior authorizations within 30 days - increased initial denials and reduced 30-day approvals to just 25%. In response to these revelations, CVRx's stock price cratered 59% on August 7, 2026. Three days later, on August 10, 2026, CVRx abruptly terminated its Chief Revenue Officer (CRO), Robert John. FOCUS OF THE HAGENS BERMAN INVESTIGATION "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer, as well as whether CVRx may have misled investors regarding the true state of its commercial sales force and Medicare Advantage reimbursement rates," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. WHAT CVRx (CVRX) INVESTORS & WHISTLEBLOWERS CAN DO * Investors: If you invested in CVRx, Inc. (NASDAQ: CVRX) and suffered significant financial losses, you can submit your losses now. * Whistleblowers: Persons with non-public information regarding CVRx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
CVRx replaces chief revenue officer amid sales shift. (Moderate) Rhea-AI filing summary. CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement. The company also announced a sales leadership transition in which Paul Verrastro, a long-time CVRx executive with more than 30 years of medical device sales and marketing experience, has been appointed Interim Head of Sales effective immediately while a search for a permanent successor is conducted. Management stated that a revised commercial outlook and the need to improve commercial execution led to the change in sales leadership. Positive. Negative. * CVRx's Chief Revenue Officer departed effective August 10, 2026, with the change explicitly linked to a revised commercial outlook and the need to improve commercial execution, signaling potential challenges in the company's current sales performance. 8-K event classification. 2 items: 5.02, 9.01 Key figures. Key terms. Emerging growth company, neuromodulation, Breakthrough Device designation, cardiac resynchronization therapy (CRT), +1 more Faq. What leadership change did CVRX (CVRX) announce in this Form 8-K? CVRx announced that Chief Revenue Officer Robert John's employment terminated effective August 10, 2026. The company has begun a transition in sales leadership following his departure under severance-eligible circumstances defined in his employment agreement. Who will lead sales at CVRX (CVRX) after the Chief Revenue Officer's departure? CVRx appointed Paul Verrastro as Interim Head of Sales effective immediately. He will oversee the sales organization while the company conducts a search for a permanent successor to the Chief Revenue Officer role. Why did CVRX (CVRX) change its sales leadership team? President and CEO Kevin Hykes stated that a revised commercial outlook and need to improve commercial execution led CVRx to change sales leadership, indicating the move is driven by current commercial performance considerations. What experience does the new Interim Head of Sales at CVRX (CVRX) have? Interim Head of Sales Paul Verrastro brings more than 30 years of medical device sales and marketing experience. He has been with CVRx for over five years and previously served as Chief Marketing and Strategy Officer and a senior advisor on commercial execution. Does Robert John receive severance in connection with his departure from CVRX (CVRX)? Yes. CVRx disclosed that Robert John's employment terminated under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the applicable conditions set forth in that agreement. What product focus does CVRX (CVRX) highlight in connection with this leadership transition? CVRx highlights Barostim, described as the first FDA-approved neuromodulation technology for improving heart failure symptoms. The device delivers electrical pulses to carotid baroreceptors to help restore autonomic balance in heart failure patients. AI-generated analysis. How Rhea-AI works. Not financial advice. Find StockTitan more easily in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Available on EDGAR 08/11/2026 - 07:09 AM Accepted by SEC EDGAR 08/11/2026 - 07:09 AM Date of report (Date of earliest event reported): (Exact name of registrant as specified in its charter) (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). On August 10, 2026, the employment of Robert John, the Chief Revenue Officer of CVRx, Inc., terminated effective immediately, under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the conditions therein. (d) Exhibits SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Filing Exhibits & attachments. 4 documents Press releases.
CVRx Inc reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with US revenue climbing 21% to $14.8 million. However, European revenue fell 31% to $900,000. The medical device company achieved an 87% gross margin, improving from 84% previously. Despite positive metrics, CVRx lowered its full-year 2026 revenue guidance to between $58 million and $60 million due to sales execution challenges. The company cited high sales force turnover, with roughly 60% of territory managers having joined within the last 18 months, straining training processes. Reimbursement showed improvement, with Medicare Advantage prior authorisation approval rates rising to 60% from 44% in 2025. Traditional Medicare claims are now paid at approximately 96% across all administrative contractors. CVRx ended the quarter with $64.6 million in cash. The company reported a net loss of $14 million, or $0.53 per share.
CVRx shares rose 11.6% to close at $5.86, driven by investor optimism following strong first-quarter 2026 results. The medical device company posted a loss of 50 cents per share on revenues of $14.8 million, with both figures exceeding Zacks Consensus Estimates. For the upcoming quarter, CVRx is expected to report a loss of $0.52 per share on revenues of $15.64 million, representing year-over-year improvements of 8.8% and 15.1%, respectively. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank of Hold. CVRx is part of the medical instruments industry, alongside companies like Steris, which gained 2.4% in the last session.